Subject: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

DESCRIPTION:

An important part of treatment planning for patients with breast cancer involves determining which patients could benefit from adjuvant cytotoxic chemotherapy. For example, for women with early-stage, invasive breast cancer (ie, cancer extending beyond the basement membrane of the mammary ducts into adjacent tissue), adjuvant cytotoxic chemotherapy consistently provides approximately an 30% relative risk reduction in 10-year breast cancer mortality regardless of patients' baseline prognosis. However, the absolute benefit of chemotherapy depends on the underlying or baseline risk of recurrence. Women with the best prognosis have tumors that are small, early-stage, estrogen receptor–positive, and are lymph node–negative. These women have an approximately 15% 10-year risk of recurrence with tamoxifen alone; which means that approximately 85% of these patients could avoid the toxicity of adjuvant cytotoxic chemotherapy if they could be accurately identified. Conventional risk classifiers estimate recurrence risk by considering criteria such as tumor size, type, grade, and histologic characteristics; hormone receptor status; and number of affected lymph nodes. No single classifier is considered a criterion standard, and several common criteria have qualitative or subjective components that add variability to risk estimates. As a result, more patients are treated with chemotherapy than can benefit. Better predictors of baseline risk could help women’s decision making, some who may prefer to avoid chemotherapy if assured that their risk is low.

Laboratory tests have been developed that detect the expression, via messenger RNA of many different genes in breast tumor tissue and combine the results into a prediction of distant recurrence risk for women with early-stage breast cancer. Test results may help providers and patients decide whether to include adjuvant chemotherapy in postsurgical management of breast cancer, to alter treatment in patients with ductal carcinoma in situ (DCIS), or to recommend extended endocrine therapy in patients who are recurrence-free at 5 years.
POSITION STATEMENT:
The use of the 21-gene reverse transcriptase-polymerase chain reaction (PT-PCR) assay (i.e., Oncotype DX®) to determine recurrence risk for deciding whether to undergo adjuvant chemotherapy meets the definition of medical necessity in members with newly diagnosed (6 months or less) primary, invasive breast cancer meeting ALL of the following criteria:

- Unilateral tumor **AND**
- Node-negative (lymph nodes with micrometastases (≤ 2 mm in size) are considered node negative) **OR** with 1-3 involved ipsilateral axillary lymph nodes **AND**
- Hormone receptor-positive (that is ER-positive or PR-positive) **AND**
- HER2-negative **AND**
- Tumor size > 0.5 cm **AND**
- Who will be treated with hormonal therapy **AND**
- Who are candidates for chemotherapy **AND**
- Who have had surgery and full pathological examination of the tumor completed **AND**
- The test result will determine if adjuvant chemotherapy will be used **AND**
- The test is ordered by the treating physician.

Use of EndoPredict™, the Breast Cancer Index™, MammaPrint®, and Prosigna™ to determine recurrence risk for deciding whether to undergo adjuvant chemotherapy meets the definition of medical necessity in members with primary, invasive breast cancer that meet the above criteria for for Oncotype DX.

Other than its use related to newly diagnosed (6 months or less) breast cancer as outlined above, all other uses of the 21-gene PT-PCR assay (i.e., Oncotype DX), EndoPredict, the Breast Cancer Index, MammaPrint, and Prosigna, including determination of recurrence risk in invasive breast cancer members with positive lymph nodes, members with bilateral disease, or to consider length of treatment with tamoxifen are considered experimental or investigational. There is a lack of clinical data in peer-reviewed literature to permit conclusions on safety, efficacy and net health outcomes.

Use of a subset of genes from the 21-gene RT-PCR assay for predicting recurrence risk in patients with noninvasive ductal carcinoma in situ (i.e., Oncotype DX® DCIS Score) to inform treatment planning following excisional surgery is considered experimental or investigational. The evidence is insufficient to permit conclusions on efficacy and net health outcomes.

All other gene expression assays (e.g., Mammastrat®, BreastOncPx™, Insight® DX Breast Cancer Profile, NexCourse® Breast IHC4, PAM50 Breast Cancer Intrinsic Classifier™, BreastPRS™, MapQuant Dx™, and BreastOncPx™.) are considered experimental or investigational. The evidence is insufficient to permit conclusions on efficacy and net health outcomes.

The following are considered experimental or investigational as the evidence is insufficient to permit conclusions on efficacy and net health outcomes:

- The use of gene expression assays to molecularly subclassify breast cancer (eg, BluePrint®)
• The use of gene expression assays for quantitative assessment of ER, PR and HER2 overexpression (eg, TargetPrint®).

BILLING/CODING INFORMATION:

CPT Coding:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81518</td>
<td>Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy</td>
</tr>
<tr>
<td>81519</td>
<td>Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score (Oncotype DX)</td>
</tr>
<tr>
<td>81520</td>
<td>Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score</td>
</tr>
<tr>
<td>81521</td>
<td>Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis</td>
</tr>
<tr>
<td>S3854</td>
<td>Gene expression profiling panel for use in the management of breast cancer treatment</td>
</tr>
<tr>
<td>0045U</td>
<td>Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score (Investigational)</td>
</tr>
</tbody>
</table>

ICD-10 Diagnosis Codes That Support Medical Necessity:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C50.011-C50.929</td>
<td>Malignant neoplasm of breast</td>
</tr>
<tr>
<td>D05.00-D05.92</td>
<td>Lobular carcinoma in situ of breast</td>
</tr>
<tr>
<td>Z17.0</td>
<td>Estrogen receptor negative status [ER-]</td>
</tr>
</tbody>
</table>

REIMBURSEMENT INFORMATION:

Reimbursement is subject to post-service medical review. The following information is required documentation to support medical necessity: physician history and physical, pathology report, treating physician visit notes that include documentation that the intention to treat or not treat with adjuvant
chemotherapy was contingent, at least in part, on the results of the test for the individual patient in question.

**LOINC Codes:**

<table>
<thead>
<tr>
<th>DOCUMENTATION TABLE</th>
<th>LOINC CODES</th>
<th>LOINC TIME FRAME MODIFIER CODE</th>
<th>LOINC TIME FRAME MODIFIER CODES NARRATIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician history and physical</td>
<td>28626-0</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim</td>
</tr>
<tr>
<td>Attending physician visit note</td>
<td>18733-6</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
<tr>
<td>Pathology Reports Sections</td>
<td>26439-0</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
<tr>
<td>Pathology Study Reports</td>
<td>27898-6</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
</tbody>
</table>

**PROGRAM EXCEPTIONS:**

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage Products:**

The following Local Coverage Determination (LCD) was reviewed on the last guideline reviewed date: Gene Expression Profiling Panel for use in the Management of Breast Cancer Treatment (L33586) located at fcso.com.

The following were reviewed on the last guideline reviewed date: MolDX LCDs located at palmettogba.com.

The following was reviewed on the last guideline revised date: MolDX: Breast Cancer Index Genetic Assay located at noridianmedicare.com.
**DEFINITIONS:**

**Adjuvant chemotherapy:** chemotherapy given in addition to surgical therapy, in order to reduce the risk of local or systemic relapse.

**ER-positive (estrogen receptor positive):** Describes cells that have a protein to which the hormone estrogen will bind. Cancer cells that are ER-positive need estrogen to grow, and may stop growing when treated with hormones that block estrogen from binding.

**Estrogen receptor:** receptor for estrogens; its presence conveys a better prognosis for breast cancers.

**Gene expression:** the detectable effect of a gene.

**HER2 (human epidermal growth factor receptor 2):** A protein involved in normal cell growth. It is found in high levels on some breast cancer cells.

**Micrometastasis:** small numbers of cancer cells that have spread from the primary tumor to other parts of the body and are too few to be picked up in a screening or diagnostic test.

**Node-negative:** being or having cancer that has not spread to nearby lymph nodes.

**PR-positive (progesterone receptor positive):** Describes cells that have a protein to which the hormone progesterone will bind. Cancer cells that are PR-positive need progesterone to grow and will usually stop growing when treated with hormones that block progesterone from binding.

**RELATED GUIDELINES:**

None applicable.

**OTHER:**

None applicable.

**REFERENCES:**


4. Blue Cross Blue Shield Association Technology Evaluation Center (TEC), Gene expression profiling in women with lymph node negative breast cancer to select adjuvant chemotherapy, TEC Assessments 2014; Volume 29.

5. Blue Cross Blue Shield Association Technology Evaluation Center (TEC), Gene Expression Profiling in Women with Lymph-Node-Positive Breast Cancer to Select Adjuvant Chemotherapy Treatment, 04/10.


13. ClinicalTrials.gov, MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes, sponsored by European Organisation for Research and Treatment of Cancer-EORTC; accessed 01/16/18.


50. National Cancer Institute, Cancer Diagnostics: Informing the Development of Tailored Cancer Therapy, 05/23/06.


COMMITTEE APPROVAL:
This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy & Coverage Committee on 12/06/18.
**GUIDELINE UPDATE INFORMATION:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/15/05</td>
<td>New Medical Coverage Guideline.</td>
</tr>
<tr>
<td>01/01/06</td>
<td>Annual HCPCS coding update: added code S3854.</td>
</tr>
<tr>
<td>09/15/06</td>
<td>Annual review: continue investigational status.</td>
</tr>
<tr>
<td>11/15/07</td>
<td>Annual review: position statements changed, description section updated, definitions section updated, guideline reformatted, references updated.</td>
</tr>
<tr>
<td>02/15/08</td>
<td>Revised position statement; updated description section, definition section and references.</td>
</tr>
<tr>
<td>01/01/09</td>
<td>Annual review: no change to position statements, description section and references updated.</td>
</tr>
<tr>
<td>11/15/09</td>
<td>Annual review: position statements updated; description section and references updated.</td>
</tr>
<tr>
<td>09/15/10</td>
<td>Annual review: position statements maintained and references updated.</td>
</tr>
<tr>
<td>11/15/10</td>
<td>Revision; formatting changes and Program Exceptions section updated.</td>
</tr>
<tr>
<td>08/15/11</td>
<td>Scheduled review; position statements maintained and references updated; formatting changes.</td>
</tr>
<tr>
<td>03/15/12</td>
<td>Revision; position statement updated; formatting changes.</td>
</tr>
<tr>
<td>10/15/12</td>
<td>Annual review; position statements maintained and references updated.</td>
</tr>
<tr>
<td>11/01/12</td>
<td>Remove CMN; formatting changes.</td>
</tr>
<tr>
<td>05/30/13</td>
<td>Revision; Program Exceptions section and references updated.</td>
</tr>
<tr>
<td>11/15/13</td>
<td>Annual review; position statements, program exception, and references updated; formatting changes.</td>
</tr>
<tr>
<td>07/01/14</td>
<td>Quarterly HCPCS update. Added code 0008M.</td>
</tr>
<tr>
<td>10/15/14</td>
<td>Annual review; position statement section, program exception section, and references updated; formatting changes.</td>
</tr>
<tr>
<td>01/01/15</td>
<td>Annual HCPCS/CPT update. Added code 81519.</td>
</tr>
<tr>
<td>Date</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11/15/15</td>
<td>Annual review; position statement, program exception, and references updated; formatting changes.</td>
</tr>
<tr>
<td>01/01/16</td>
<td>Annual HCPCS/CPT update; code S3854 deleted.</td>
</tr>
<tr>
<td>07/01/16</td>
<td>Quarterly HCPCS/CPT update. Added code S3854 (code reinstated).</td>
</tr>
<tr>
<td>02/15/17</td>
<td>Revision; description, position statements, and references updated; formatting changes.</td>
</tr>
<tr>
<td>01/01/18</td>
<td>Annual CPT/HCPCS update. Added codes 81520, 81521; deleted code 0008M.</td>
</tr>
<tr>
<td>03/15/18</td>
<td>Review; position statements maintained; description section, coding, and references updated.</td>
</tr>
<tr>
<td>07/01/18</td>
<td>Quarterly CPT/HCPCS update. Added code 0045U.</td>
</tr>
<tr>
<td>12/15/18</td>
<td>Revision; MammaPrint added to list of tests meeting the definition of medical necessity for specific indications; investigational for all others; coding, program exception, and references updated.</td>
</tr>
<tr>
<td>01/01/19</td>
<td>Annual CPT/HCPCS coding update. Added code 81518.</td>
</tr>
<tr>
<td>02/15/19</td>
<td>Revision; Coding section, program exception section, and references updated.</td>
</tr>
</tbody>
</table>